What LifePharma does

LifePharma (legal entity LIFEPharma FZE) is a UAE-based pharmaceutical manufacturer founded in 2011 in the Jebel Ali Free Zone, Dubai, operating as the pharmaceutical manufacturing arm of VPS Healthcare. The company manufactures generic pharmaceutical products across multiple therapeutic categories including oncology/immunomodulators, cardiovascular, antiviral, antihistamine, antibiotic, anti-diabetic, gastrointestinal, and vitamin products, with additional pipeline products in anticoagulants and ophthalmics. Its manufacturing platform features cGMP-compliant automated production lines with electronic manufacturing and testing controls, an annual capacity of 2.2 billion tablets, 600 million capsules, and 30 million liquid bottles, and holds the unique distinction of being the only USFDA-approved pharmaceutical manufacturer in the UAE, alongside EMA, Health Canada, TGA Australia, and UAE GMP certifications.

LifePharma sells its products through B2B channels including direct sales to UAE healthcare providers, export distribution partnerships serving 16+ countries (USA, Canada, Australia, Africa, MENA, and Asia-Pacific), and distribution through its parent VPS Healthcare's network of 24 hospitals and 125+ health centers. The company also offers contract manufacturing and co-development services for branded generics and specialty molecules. Pricing is quote-based and negotiated by volume, product, and regulatory market.

In May 2026, LifePharma announced a Dh700 million strategic expansion at KEZAD in Abu Dhabi in partnership with AD Ports and financed by Ajman Bank, adding a fill-and-finish vaccine plant, oncology manufacturing segment, advanced injectables facility, and a Dh100 million gene therapy initiative targeting rare inherited blood disorders. The expansion is projected to generate Dh2 billion in GDP impact and create over 1,000 skilled jobs, substantially extending LifePharma's scale, therapeutic breadth, and position within UAE's pharmaceutical localization strategy.

Name

LifePharma

Legal name

LIFEPharma

Website

https://lifepharmafze.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

LifePharma is a UAE-based generic pharmaceutical manufacturer and subsidiary of VPS Healthcare, producing tablets, capsules, liquids, and injectables across oncology, cardiovascular, antiviral, and other therapeutic categories for healthcare providers and distributors in 16+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceutical manufacturing
• Contract manufacturing services
• Oncology generic drugs
• CGMP certified manufacturing
• Finished dosage formulations

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and sale of generic pharmaceutical products including tablets, capsules, liquids, injectables, and specialty drugs. Revenue generated through direct sales to healthcare providers, pharmacies, hospitals, and distribution partnerships across global markets including UAE, USA, Europe, Australia, Canada, Africa, and Asia.
2. Contract Manufacturing: Development and manufacturing services for branded generics and specialty molecules under partnerships and co-development agreements, supporting market expansion in USA, Canada, GCC, and MENA regions.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

LIFEPharma manufactures and supplies generic pharmaceutical products across multiple therapeutic categories including oncology, cardiovascular, antiviral, antihistamine, antibiotic, and specialty drugs in tablet, capsule, liquid, injectable, and ophthalmic dosage forms. The company also offers contract manufacturing and co-development services for branded generics and specialty molecules. Production is conducted at its USFDA-approved Dubai facility with capacity for 2.2 billion tablets, 600 million capsules, and 30 million liquid bottles per annum.

Product overview

LIFEPharma is the UAE's only USFDA-approved pharmaceutical manufacturer and part of VPS Healthcare. The company operates a Dubai-based manufacturing facility producing a comprehensive portfolio of generic pharmaceutical products across multiple therapeutic categories including: Oncology/Immunomodulators (Abiraterone, Everolimus, Imatinib, Lenalidomide, Letrozole, Anastrazole, Bendamustine, Gefitinib, Sorafenib), Anti-adhesion (Antijoin), Anticoagulants (Clopimet, Apixaban pipeline), Antiflatulants (Gastrex, Spasmolife), Antivirals (Avilife/Favipiravir, Seltaflu/Oseltamivir), Antihistamines/Cough Preparations (Coldifed, Coldifed-P, Destalife, Kufdrin, Loralife, Mukinate, Telife, Ventamol), Antihyperlipidemics (Lipira, Rosulife), Antihypertensives (Maldocardin, Micastan, Nebilife, Concolife), Erectile Dysfunction (Vigalife), Beta Lactam Antibiotics (Comoxlife, Amoxilife), Laxatives (Lifulax), Macrolide Antibiotics (Henacyl, Klarith, Klarith ER), Multiple Sclerosis (Strilenya), Neuropathy (Starica), NSAIDs (Ibulife, Panalife family), Oral Hypoglycemic Agents (Glimelife, Pio, DiaLife MR), Proton Pump Inhibitors (Esolife GR, Esolife DR, Pantolife), and Vitamins (C-Vit Daily Orange, Folilife, Trivit). The facility has production capacity of 2.2 billion tablets, 600 million capsules, and 30 million liquid bottles per annum. The company is expanding with a Dh700 million pharmaceutical manufacturing platform at KEZAD.

Differentiator

Problem solved

Functional benefit

Products and services

• Abiraterone Tablets Abiraterone acetate tablets (250mg) for the treatment of prostate cancer, offered as a generic oncology product for hospitals, pharmacies, and healthcare providers.
• Imatinib Tablets Imatinib tablets (100mg, 400mg), a tyrosine kinase inhibitor for chronic myelogenous leukemia and acute lymphocytic leukemia, supplied as a generic oncology product.
• Antijoin PFS Pre-filled syringe containing hydroxyethyl starch and sodium hyaluronate (25mg + 50mg) for prevention of surgical adhesions during C-section and laparoscopy procedures.
• Clopimet Tablets Clopidogrel bisulfate tablets (75mg), an anticoagulant to reduce risk of heart disease and stroke, commonly used in combination with aspirin.
• Avilife Tablets Favipiravir 200mg tablets for antiviral treatment including COVID-19, supplied as a branded generic to hospitals, pharmacies, and distributors.
• Ventamol Syrup Salbutamol sulfate syrup for treatment of wheezing and shortness of breath caused by asthma and chronic obstructive pulmonary disease (COPD).
• Lipira Tablets Atorvastatin calcium tablets (10mg, 20mg) to prevent cardiovascular disease in high-risk patients and treat abnormal lipid levels.
• Maldocardin Tablets Amlodipine besilate tablets (5mg, 10mg) for antihypertensive treatment, supplied as a generic cardiovascular product.
• Comoxlife Tablets Co-amoxiclav tablets (625mg, 1g) for treatment of middle ear, sinus, throat, lung respiratory tract, and urinary tract infections.
• Strilenya Capsules Fingolimod hydrochloride 0.5mg capsules for relapsing forms of multiple sclerosis to reduce frequency of clinical exacerbations and delay physical disability.
• Esolife GR Tablets Esomeprazole magnesium amorphous gastro-resistant tablets (20mg, 40mg) for GERD treatment and NSAID-associated gastric ulcer risk reduction.
• Contract Manufacturing Services Development and manufacturing services for branded generics and specialty molecules under partnerships and co-development agreements, supporting market expansion in USA, Canada, GCC, and MENA regions.
• Panalife Tablets Paracetamol syrup and tablets for mild to moderate pain and fever reduction, supplied as an over-the-counter generic product.
• Glimelife Tablets Glimepiride tablets (2mg, 4mg) as oral hypoglycemic agent for diabetes management.
• Telife Tablets Fexofenadine HCl tablets (120mg, 180mg) for relief of allergy symptoms such as hay fever and urticaria.

Quantifiable outcome

• Dh2 billion GDP impact projected from KEZAD expansion
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

• AD PortsflagshipStrategic or Co-development Partner · 4 May 2026Strategic MoU signed with AD Ports to develop a Dh700 million advanced pharmaceutical manufacturing platform at Khalifa Economic Zones Abu Dhabi (KEZAD). The platform comprises three facilities: Dh300 million fill-and-finish vaccine plant, Dh200 million oncology segment, and Dh200 million advanced injectables facility. Projected to generate Dh2 billion in GDP impact and create over 1,000 skilled jobs.
• Emirates Pharmaceutical FoundationcoreStrategic or Co-development PartnerLIFEPharma participated in field visits organized by Emirates Pharmaceutical Foundation to discuss development and expansion plans aligned with UAE's strategy to localize advanced therapeutic technologies. The visits focused on production capabilities, modern manufacturing technologies, and growth requirements.
• Canadian Pharmaceutical CompanyminorStrategic or Co-development PartnerStrategic collaboration with Canadian pharmaceutical company to support operations in GCC region and initiate new business in GCC and MENA region. Also enabled first commercial manufacturing for Canadian market.

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

Others

• Sun Pharmaceutical Industries:

Direct peers

• Aurobindo Pharma: Indian-headquartered global generic manufacturer with one of the largest US ANDA portfolios and a strong injectables franchise. Direct peer on USFDA-approved manufacturing, ANDA-driven US growth, and expanding specialty/injectable capacity, representing the benchmark for scale generic manufacturing.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharmaceutical manufacturer with significant MENA, US, and Europe presence. Comparable business model of branded generics, injectables, and specialty pharma sold across regulated and emerging markets; closest large-cap analog to LifePharma's geographic and product strategy.
• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic pharmaceutical manufacturer producing tablets, capsules, syrups, and injectables across multiple therapeutic categories. Closest regional peer to LifePharma given shared UAE base, MENA distribution focus, and similar generic product mix including cardiovascular and anti-infectives.
• Cipla: Indian-headquartered global generic pharmaceutical major with a broad portfolio across respiratory, cardiovascular, anti-infectives, and oncology, plus US ANDA filings and emerging market reach. Direct peer on USFDA-compliant manufacturing, ANDA pipeline, and US/MENA distribution model.
• Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with a major generics business (tablets, injectables, biosimilars) and strong USFDA-approved manufacturing footprint. Direct peer on US generic ANDA pipeline, regulated-market injectable expansion, and emerging market presence.
• Neopharma: Abu Dhabi-based generic pharmaceutical manufacturer with global GMP approvals and a multi-therapy portfolio including oncology, cardiology, and anti-infectives. Direct peer to LifePharma with overlapping GCC footprint, similar regulatory positioning, and parallel expansion into specialty/injectable manufacturing.
• Aspen Pharmacare: South African-headquartered global specialty and generic pharmaceutical company with strong emerging market presence in Africa, MENA, and Asia-Pacific. Direct peer given LifePharma's footprint in African and MENA markets and similar focus on affordable specialty generics including oncology.

Broad incumbents

• Teva Pharmaceutical Industries: Israeli-headquartered global generic pharmaceutical leader and the world's largest generics manufacturer, with broad portfolios across generics, specialty, and biosimilars. Broad incumbent in the same generic pharmaceutical space with overlapping therapeutic categories and far larger global scale.
• Sandoz (Novartis division): Global generic and biosimilar pharmaceutical company spun out of Novartis, with a leading position in generic tablets, injectables, and biosimilars across Europe, US, and emerging markets. Broad incumbent peer with USFDA/EMA-equivalent manufacturing footprint and a comparable injectable/specialty strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lifepharma2
• Facebookfacebook.com/LIFEPharmaUAE
• LinkedInlinkedin.com/company/lifepharma

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifePharma